SCHEMBL4626639

SCHEMBL4626639

COc1ccccc1-c1cc(=O)c2cc(O)ccc2o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 7/20 1.00
HPGD P15428 6/20 1.00
CYP2C19 P33261 4/20 1.00
ALDH1A1 P00352 4/20 1.00
TSHR P16473 3/20 1.00
AR P10275 1/20 0.74
CSNK2A2 P19784 4/20 0.65
CSNK2B P67870 4/20 0.65
CSNK2A1 P68400 4/20 0.65
FYN P06241 1/20 0.65
ESR2 Q92731 1/20 0.64
AHR P35869 1/20 0.62
MAPT P10636 7/20 0.61
MEN1 O00255 5/20 0.61
KMT2A Q03164 5/20 0.61
NPC1 O15118 4/20 0.61
RAB9A P51151 4/20 0.61
NFKB1 P19838 1/20 0.61
RECQL P46063 1/20 0.61
NFKB2 Q00653 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31675843 1.00 CYP3A4 (1.00) CYP3A4HPGDCYP2C19ALDH1A1TSHR
SCHEMBL4650574 0.90 HPGD (0.81) CYP3A4HPGDCYP2C19ALDH1A1TSHR
SCHEMBL30660103 0.85 AR (1.00) CYP3A4HPGDCYP2C19ALDH1A1TSHR
SCHEMBL5580084 0.85 ALDH1A1 (0.74) CYP3A4HPGDCYP2C19ALDH1A1TSHR
SCHEMBL4443406 0.85 AR (1.00) CYP3A4HPGDCYP2C19ALDH1A1TSHR
SCHEMBL253522 0.85 HPGD (0.78) CYP3A4HPGDCYP2C19ALDH1A1TSHR
SCHEMBL17786446 0.84 AR (0.74) CYP3A4HPGDCYP2C19ALDH1A1TSHR
SCHEMBL11562791 0.84 ALDH1A1 (0.72) CYP3A4HPGDCYP2C19ALDH1A1TSHR
SCHEMBL7583434 0.82 HPGD (0.70) CYP3A4HPGDCYP2C19ALDH1A1TSHR
SCHEMBL30143812 0.82 HPGD (0.78) CYP3A4HPGDCYP2C19ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
EP-2730431-B1 Rubber composition and tire with rubber containing flavone GOODYEAR TIRE & RUBBER (US) 2017-06-28 EP disclosed
US-20140135433-A1 TIRE WITH RUBBER CONTAINING FLAVONE THE GOODYEAR TIRE & RUBBER COMPANY (US) 2014-05-15 US disclosed
EP-2730431-A1 Rubber composition and tire with rubber containing flavone The Goodyear Tire & Rubber Company (US) 2014-05-14 EP disclosed
EP-1391327-B1 Tire with rubber containing flavone GOODYEAR TIRE & RUBBER (US) 2008-09-03 EP disclosed
EP-1542676-A4 METHODS OF TREATING BENZODIAZEPINE SITE (BZD-S) ASSOCIATED SYNDROMES USING 2' HYDROXYFLAVONOIDS PHARMACOGENETICS LTD (CN) 2008-04-30 EP disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 US disclosed
EP-1542676-A1 METHODS OF TREATING BENZODIAZEPINE SITE (BZD-S) ASSOCIATED SYNDROMES USING 2' HYDROXYFLAVONOIDS Phamacogenetics Limited (CN) 2005-06-22 EP disclosed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US disclosed
US-6740677-B2 ANXIETY, CONVULSIONS NATURON LIMITED (HK) 2004-05-25 US disclosed
WO-2004016265-A1 METHODS OF PREDICTING GABAA RECEPTOR EFFICACIES FOR FLAVONOID COMPOUNDS AND USES THEREFOR PHAMACOGENETICS LIMITED (CN) 2004-02-26 WO disclosed
WO-2004016266-A1 METHODS OF TREATING BENZODIAZEPINE SITE (BZD-S) ASSOCIATED SYNDROMES USING 2’ HYDROXYFLAVONOIDS PHAMACOGENETICS LIMITED (CN) 2004-02-26 WO disclosed
EP-1391327-A1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2004-02-25 EP disclosed
US-20040034092-A1 Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2' hydroxyflavonoids NATURON LIMITED (CN) 2004-02-19 US disclosed
EP-1355898-A1 METHOD FOR PRODUCING FLAVONE DERIVATIVES MERCK PATENT GmbH (DE) 2003-10-29 EP disclosed
WO-2003057210-A1 COMPOSITIONS AND METHODS FOR INCREASING CELL PROLIFERATION COMPRISING A FLAVONOID KIMBERLY-CLARK WORLDWIDE, INC. (US) 2003-07-17 WO disclosed
US-20030125264-A1 Methods For Treating Wounds KIMBERLY-CLARK WORLDWIDE, INC. 2003-07-03 US disclosed
WO-2002060889-A1 METHOD FOR PRODUCING FLAVONE DERIVATIVES MERCK PATENT GMBH (DE) 2002-08-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 CYP3A4 17/4885HPGD 1949/4885CYP2C19 185/4885
US-20040034092-A1 Methods of treating benzodiazepine site (BZD-S) associated syndromes using 2' hydroxyflavonoids GABBR1, GABBR2, GABRB2 CYP3A4 106/4885HPGD 350/4885CYP2C19 97/4885
US-20030125264-A1 Methods For Treating Wounds FGF2, MMP1, FIBP CYP3A4 3010/4885HPGD 558/4885CYP2C19 2389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.